Skip to main content
Clinical Trials/ISRCTN23256704
ISRCTN23256704
Active, not recruiting
未知

Psychosis Immune Mechanism Stratified Medicine Trial: The PIMS Trial

niversity of Bristol0 sites120 target enrollmentJuly 13, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Psychosis
Sponsor
niversity of Bristol
Enrollment
120
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36963796/ (added 10/05/2023)

Registry
who.int
Start Date
July 13, 2022
End Date
May 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Bristol

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria for All Participants
  • 1\. Able and willing to give informed consent, including consent to share information with the participant’s General Practitioner (GP) and to access secondary care and GP records.
  • 2\. Able to understand written and spoken English.
  • 3\. Willing to consent to blood sampling.
  • 4\. Willing to abstain from strenuous exercise for 72 hours before the assessment visits.
  • 5\. Age: 18 \- 40 years (inclusive) at the time of eligibility assessment.
  • Additional Inclusion Criteria for Neuroimaging
  • 6\. Able and willing to consent to MRI scanning.
  • Additional Inclusion Criteria for Healthy Controls
  • 7\. No current or lifetime psychiatric diagnosis.

Exclusion Criteria

  • Exclusion Criteria for All Participants
  • 1\. Pregnancy (confirmed by urine pregnancy test) or breast feeding.
  • 2\. Body mass index (BMI) \>35 kg/m² (i.e., WHO obesity class II or above).
  • 3\. Current or lifetime diagnosis of antisocial personality disorder, autism or other neurodevelopmental disorder, major traumatic brain injury (determined by Chief Investigator).
  • 4\. Currently active diagnosed eating disorder likely to compromise ability to take part (determined by Chief Investigator).
  • 5\. History of alcohol or substance use disorder (abuse/dependence) within six months prior to eligibility assessment (nicotine and caffeine dependence are not exclusionary).
  • 6\. Current use of medication likely to compromise interpretation of immunological data (including, but not limited to, antibiotics, regular non\-steroidal anti\-inflammatory drugs, oral/injectable corticosteroids – or any other substances to be determined by the Chief Investigator).
  • 7\. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections.
  • 8\. Current or past infection including tests for TB, Hepatitis B, Hepatitis C, VZV or HIV confirmed by blood test. Chest X\-ray will be also done to exclude TB.
  • 9\. Any major episode of infection requiring hospitalisation or treatment with IV antibiotics within 4 weeks of eligibility assessment.

Outcomes

Primary Outcomes

Not specified

Similar Trials